Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs
Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
Camille Edwards, M.D., et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen
https://www.tandfonline.com/doi/abs/10.1080/13506129.2020.1778461
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13472
AL Amyloidosis in Myeloma: Red Flag Symptoms
https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(20)30280-9/pdf#secsectitle0025
Novel semi-automated algorithm for high-throughput quantification of adipocyte size in breast adipose tissue, with applications for breast cancer microenvironment
https://www.tandfonline.com/doi/full/10.1080/21623945.2020.1787582